IBRXIBRXHealthcare · Biotechnology

IBRX Stock Forecast: ImmunityBio, Inc. Price Predictions for 2026-2027

Last close, 17 Nov 2026
$6.26
+4.68% on the day

The 4 Wall Street analysts covering ImmunityBio, Inc. hold a median 12-month price target of $15 — +131.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 40 of 100 as at 16 Nov 2026 — in the lower half.

Market cap
$6.4B
Ticker Nerd rank
40/ 100
Median analyst target
$15
Analysts covering
4
Revenue$51.2M+93.9% y/y
Operating income−$61.7M
Net income−$230.4M
Free cash flow−$70.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−7.2%
1M
−31.8%
YTD
+216.2%
1Y
+208.4%
From 52W high
−45.8%
From 52W low
+216.2%
$2
$12
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

IBRX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores ImmunityBio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 16 Nov 2026
40/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
92
Value
91
Momentum
83
Quality
42
Growth
41
Revisions
28
Volatility
25
Size
20
Issuance
8

Accruals (92): Reported profit is backed by cash, and the company is not expanding recklessly.

Issuance (8): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

IBRX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on IBRX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15Jan 26Apr 26Jul 26Oct 26IBRXHigh $16Median $15Low $12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
4 Buy0 Hold0 Sell
Low $12Median $15High $16

The green dot is the last close — the median target sits +131.6% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
15 Oct 2026HC Wainwright & Co.ReiteratesBuy$15
15 Oct 2026JefferiesMaintainsBuy$12 → $14
2 June 2026HC Wainwright & Co.ReiteratesBuy$15
2 June 2026HC Wainwright & Co.ReiteratesBuy—
21 May 2026BTIGReiteratesBuy—
20 May 2026HC Wainwright & Co.ReiteratesBuy—
5 May 2026D. Boral CapitalMaintainsBuy—
21 Apr 2026D. Boral CapitalMaintainsBuy—
8 Apr 2026D. Boral CapitalMaintainsBuy—
26 Mar 2026D. Boral CapitalMaintainsBuy—
23 Mar 2026D. Boral CapitalMaintainsBuy—
17 Mar 2026D. Boral CapitalMaintainsBuy—
12 Mar 2026BTIGAssumesBuy$13
9 Mar 2026D. Boral CapitalMaintainsBuy—
4 Mar 2026Piper SandlerReiteratesOverweight—
23 Feb 2026D. Boral CapitalMaintainsBuy—
23 Feb 2026HC Wainwright & Co.MaintainsBuy—
19 Feb 2026D. Boral CapitalMaintainsBuy—
17 Feb 2026D. Boral CapitalMaintainsBuy—
26 Jan 2026HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

IBRX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

IBRX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 17 Nov 2026, ImmunityBio, Inc. returned +208.4% against +11.2% for the S&P 500, dividends included.

IBRX vs S&P 500, last 12 monthsTotal return, rebased to 100
100200300400500Jan 26Apr 26Jul 26Oct 26IBRXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

IBRX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
1
Fundamentals

ImmunityBio, Inc. (IBRX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−15.8×

Cheaper than 96% of US stocks

Price / sales
34.8×

Cheaper than 6% of US stocks

Price / book
−6.0×

Cheaper than 98% of US stocks

EV / EBITDA
−28.6×

Cheaper than 92% of US stocks

Growth & margins
Revenue growth (YoY)
52.3%

Higher than 86% of US stocks

Earnings growth (YoY)
93.9%

Higher than 83% of US stocks

Gross margin
99.4%

Higher than 99% of US stocks

Operating margin
−150.2%

Higher than 12% of US stocks

Net margin
99.3%

Higher than 99% of US stocks

Returns & dividend
Return on equity
70.3%

Higher than 95% of US stocks

Return on assets
−30.4%

Higher than 14% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

ImmunityBio, Inc. (IBRX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • ImmunityBio, Inc. has a market value of $6.4B and an enterprise value of $7.4B.

  • Revenue in the twelve months to 30 June 2026: $165.8M. The latest quarter grew 52.3% year on year.

  • Net income over the same four quarters: −$992.4M, a −598.6% net margin.

  • Diluted earnings per share, trailing twelve months: −$0.97.

  • Free cash flow in the twelve months to 30 June 2026: −$288.5M.

  • Shares outstanding: 1.1B.

  • Trailing P/E: −15.8×; forward P/E: −54.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • ImmunityBio, Inc. employs 684 people — $242K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 17 Nov 2026

Data provided by Twelve Data

Peers

IBRX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
IBRXImmunityBio, Inc.$6.4B40
ARWRArrowhead Pharmaceuticals, Inc.$6.2B41
LGNDLigand Pharmaceuticals, Inc.$6.0B68
ORKAOruka Therapeutics, Inc.$6.6B37
KODKodiak Sciences, Inc.$6.6B59
MIRMMirum Pharmaceuticals, Inc.$5.9B56
CAICaris Life Sciences, Inc.$5.9B25

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own ImmunityBio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest IBRX news & analysis

ImmunityBio, Inc. (IBRX) Presents at UBS Global Biopharma Conference 2026 Prepared Remarks Transcript

Seeking Alpha · 16 Nov 2026neutral

ImmunityBio CEO Richard Adcock presented prepared remarks at the UBS Global Biopharma Conference 2026. The excerpt identifies the company and conference participants but does not include the substance of the remarks.

Why it matters — IBRX watchers can note the company’s participation in the conference, though the excerpt provides no business or clinical updates.

New U.S. Survey of Military Service Members and Veterans with Non-Muscle Invasive Bladder Cancer Reveals 53% Were Diagnosed at Age 50 or Younger and Barriers to Care

Business Wire · 11 Nov 2026neutral

ImmunityBio announced findings from a national survey of military service members and veterans with non-muscle invasive bladder cancer, conducted by The Harris Poll on the company’s behalf. The survey found that 53% of respondents were diagnosed at age 50 or younger and 63% reported barriers or challenges to receiving treatment.

Why it matters — The findings provide context on diagnosis age and reported treatment-access challenges among this patient group relevant to ImmunityBio’s bladder-cancer focus.

ImmunityBio to Participate in UK Investor Conferences During London Life Sciences Week 2026

Business Wire · 11 Nov 2026neutral

ImmunityBio said senior leaders will speak at the Jefferies Global Healthcare Conference and UBS Global Biopharma Conference in London during Life Sciences Week 2026, November 15–20. The announcement also referenced results from its QUILT-2.005 study.

Why it matters — IBRX watchers may note the planned investor-conference appearances and the company’s reference to its bladder cancer study.

IBRX Q3 Earnings Miss, Anktiva Sales Decline Q/Q, Stock Down 18%

Zacks Investment Research · 10 Nov 2026negative

ImmunityBio reported a 53% revenue increase on Anktiva adoption, but its loss was wider than expected, Anktiva sales declined sequentially, and expenses rose. The stock was down 18%.

Why it matters — IBRX watchers may note the contrast between revenue growth and weaker sequential sales, rising expenses, and a wider-than-expected loss.

Why ImmunityBio Stock Dropped 15% After Earnings Despite 53% Sales Growth. Is IBRX Now a Buy?

The Motley Fool · 9 Nov 2026negative

ImmunityBio’s quarterly product sales rose 53% year over year but fell from the prior quarter and missed Wall Street’s estimate. The excerpt also notes the stock’s valuation at roughly 39 times annualized sales and the company’s warning of substantial doubt about continuing without additional funding.

Why it matters — IBRX watchers may weigh the sales growth against the sequential decline, missed estimate, and stated need for additional funding.

FAQ

Frequently asked questions about IBRX stock

What is the IBRX stock price forecast for 2026-2027?

The 4 Wall Street analysts covering ImmunityBio, Inc. have a median 12-month price target of $15, with estimates ranging from $12 to $16. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is IBRX stock a buy right now?

Of the 4 analysts covering ImmunityBio, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks ImmunityBio, Inc. 40 out of 100 across roughly 4,600 US stocks as at 16 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank IBRX?

As at 16 Nov 2026, ImmunityBio, Inc. ranks 40 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (92 of 100).

Will IBRX stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +131.6% from the last close, and Ticker Nerd's factor model ranks ImmunityBio, Inc. 40 out of 100 as at 16 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the IBRX stock forecast for 2030?

No analyst covering ImmunityBio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IBRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $16 over the next 12 months.

How has IBRX stock performed over the past year?

ImmunityBio, Inc. returned +208.4% over the 12 months to 17 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does ImmunityBio, Inc. do?

ImmunityBio Inc. is a biotechnology company focused on developing and commercializing immunotherapies that activate the body’s innate and adaptive immune systems.

What is the latest news on IBRX?

The most recent item we track (Seeking Alpha, 16 Nov 2026): "ImmunityBio, Inc. (IBRX) Presents at UBS Global Biopharma Conference 2026 Prepared Remarks Transcript". ImmunityBio CEO Richard Adcock presented prepared remarks at the UBS Global Biopharma Conference 2026. The excerpt identifies the company and conference participants but does not include the substance of the remarks.

Company

About ImmunityBio, Inc.

ImmunityBio Inc. is a biotechnology company focused on developing and commercializing immunotherapies that activate the body’s innate and adaptive immune systems. Its current portfolio centers on ANKTIVA, a lead biologic product used with BCG for adults with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company also works on additional biologic platforms, including cytokine fusion proteins, DNA and vaccine vectors, NK-cell therapies, and other immunomodulators for cancer and infectious diseases. ImmunityBio’s products and research programs are aimed at addressing unmet needs in oncology and infectious disease treatment through immune-based approaches. Headquartered in San Diego, California, ImmunityBio operates as a commercial-stage company with a focus on bringing biologic therapies from development into clinical use.

CEO Mr. Richard Gerald Adcock · 684 employees · United States · https://immunitybio.com